GCG and type 2 diabetes mellitus: Given the strict eligibility criteria for metabolic surgery, newer pharmaceutical antidiabetic approaches, especially those incretin-based medications, with remarkable reduction effects on blood glucose as well as body fat (in ectopic/visceral depots), should be prioritized in treating T2DM as they have been proved metabolic beneficial in preventing/ameliorating cardiovascular and renal complications.